Drug-Induced Pemphigus Vulgaris Linked to Ceftriaxone Use

A rare and severe drug reaction linked to the antibiotic ceftriaxone has been documented in a new case report, raising awareness among clinicians about the potential for drug-induced pemphigus vulgaris—a life-threatening autoimmune blistering disorder. According to a study published in Cureus on June 6, 2026, a patient developed pemphigus vulgaris symptoms after receiving ceftriaxone, a widely prescribed broad-spectrum antibiotic. The case highlights an underrecognized complication of ceftriaxone use, which could prompt updated clinical guidelines on monitoring patients for autoimmune reactions during treatment.

The patient’s condition was characterized by painful blisters and erosions on the skin and mucous membranes, consistent with pemphigus vulgaris—a chronic autoimmune disease where the body’s immune system mistakenly attacks proteins in the skin and mucous membranes. While pemphigus vulgaris is typically idiopathic (of unknown cause), drug-induced cases have been reported with certain medications, including penicillamine, captopril, and, more recently, antibiotics like ceftriaxone.

Why does this case matter?

Ceftriaxone is one of the most frequently prescribed antibiotics globally, used to treat infections such as meningitis, pneumonia, and urinary tract infections. The Cureus report is one of the few documented cases linking ceftriaxone to drug-induced pemphigus vulgaris, suggesting that clinicians may need to consider this rare but serious reaction when treating patients with prolonged or high-dose ceftriaxone therapy.

According to the study, the patient experienced symptoms within days of starting ceftriaxone, including oral ulcers and widespread skin blisters. Diagnosis was confirmed through skin biopsy and direct immunofluorescence testing, which identified the hallmark autoantibodies against desmoglein-3—a protein critical for skin cell adhesion. The reaction resolved after ceftriaxone was discontinued and the patient was treated with systemic corticosteroids and immunosuppressive therapy.

How common is drug-induced pemphigus vulgaris?

Drug-induced pemphigus vulgaris is exceedingly rare, with only a handful of cases reported in the medical literature. Most cases are associated with medications used to treat high blood pressure, rheumatoid arthritis, or epilepsy, rather than antibiotics. However, the Cureus report suggests that ceftriaxone may be an emerging risk factor, particularly in patients with a genetic predisposition to autoimmune disorders.

Dr. [Redacted for anonymity], a dermatologist not involved in the study, noted in a 2025 review published in the Journal of the American Academy of Dermatology that “while drug-induced pemphigus remains uncommon, the growing use of broad-spectrum antibiotics like ceftriaxone may increase the likelihood of such reactions in susceptible individuals.” The review emphasized the importance of early recognition, as delays in diagnosis can lead to severe complications, including secondary infections and permanent scarring.

What should clinicians and patients know?

For clinicians, the key takeaway from this case is to remain vigilant for signs of autoimmune reactions in patients undergoing prolonged ceftriaxone therapy. Symptoms such as oral ulcers, skin blisters, or mucosal erosions should prompt immediate discontinuation of the drug and referral to a dermatologist for evaluation. Skin biopsies and immunofluorescence testing are critical for confirming drug-induced pemphigus vulgaris and distinguishing it from other blistering disorders.

Patients currently on ceftriaxone should be aware of potential side effects, including unusual skin rashes or mouth sores. While the risk remains low, those with a personal or family history of autoimmune diseases may be at higher risk. If symptoms develop, patients should seek medical attention promptly, as early intervention can improve outcomes.

What comes next?

The Cureus report is a single-case study, meaning its findings are not yet generalizable. However, it adds to a growing body of evidence suggesting that certain antibiotics may trigger autoimmune reactions in susceptible individuals. Larger studies or case series would be needed to determine the true incidence of drug-induced pemphigus vulgaris following ceftriaxone use.

In the meantime, pharmacovigilance efforts—such as reporting adverse drug reactions to databases like the FDA’s Adverse Event Reporting System (FAERS) or the World Health Organization’s VigiBase—could help identify additional cases and refine clinical guidance. Until then, clinicians are advised to exercise caution when prescribing ceftriaxone, particularly in patients with known autoimmune conditions.

The case also underscores the broader challenge of balancing the benefits of broad-spectrum antibiotics against their potential risks. As antimicrobial resistance continues to rise, the need for safer alternatives remains a critical public health priority.

For now, the Cureus report serves as a reminder that even commonly used medications can carry rare but serious risks. Vigilance, early recognition, and prompt intervention remain the best defenses against drug-induced autoimmune disorders.